Exactus (OTC: EXDI) is a life science company developing and commercializing point-of-care (POC) diagnostics for measuring proteolytic enzymes in the blood. The company’s lead product, the FibriLyzer™, is being developed to assess the fibrinolytic status to speed treatment decisions for patients who are at risk of hemorrhage. The company’s second product candidate, the MatriLyzer™, may be used to detect the recurrence of cancer and can be used as an at-home monitoring device or during routine office visits. The MatriLyzer™ can communicate directly with the attending oncologist via a smart phone application to ensure that the tests are being used properly and to notify when collagenase levels are elevated signaling the need for the patient to have a more thorough examination. For more information, visit the company’s website at www.exactusinc.com.
About NetworkNewsWire
NetworkNewsWire (NNW) is an information service that provides to users (1) access to our news aggregation and syndication servers, (2) enhanced press release services, and (3) a full array of social communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
NetworkNewsWire (NNW)
New York, New York
www.networknewswire.com
212.418.1217 Office
Editor@NetworkNewsWire.com
